Longeveron (NASDAQ:LGVN) stock is rocketing higher on Wednesday after the clinical-stage biotechnology company announced a new designation from the Food and Drug Administration (FDA).The FDA has granted Longeveron’s Lomecel-B the Regenerative Medicine Advanced Therapy (RMAT) designation. This is the company’s treatment for mild Alzheimer’s Disease.This is big news for LGVN stockholders as it marks the first time the RMAT designation has been granted to a cellular therapeutic Alzheimer’s treatment candidate. ...